报价延迟最少15分钟:2026/04/25 04:13 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.08 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.59/1.00
|
|
企业价值
14.48B
|
| 资产负债 |
|
每股账面净值
9.13
|
| 现金流量 |
|
现金流量率
0.23
|
| 损益表 |
|
收益
7.52B
|
|
每股收益
10.16
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses onproducts derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products. |
